Zymeworks Inc.

What they do

Zymeworks manages a portfolio of licensed healthcare assets and develops novel multifunctional biotherapeutics for cancer, inflammation, and autoimmune disease using its multispecific antibody (MSAT) and antibody-drug conjugate (ADC) platforms. It partners programs with larger pharmaceutical companies to share development risk and cost in exchange for milestones and royalties, while retaining some wholly-owned pipeline assets. Its most advanced partnered asset is zanidatamab (Ziihera), which generates royalty revenue today.

Revenue drivers

• Zanidatamab royalties (Ziihera) — Royalties from Jazz Pharmaceuticals and BeOne Medicines on net sales of Ziihera; royalty revenue was $1.8 million in Q2 2026.
• Regulatory milestones — Potential lump-sum payments for approvals, including a $250 million U.S. approval milestone and up to $190 million in additional global regulatory milestones for 1L HER2+ GEA.
• License and collaboration revenue — Upfront, milestone, and reimbursement payments from partners; annual revenue was $106.0 million in 2025, but quarterly revenue fell to $4.6 million in Q2 2026.
• Theravance acquisition (pending) — Proposed acquisition expected to close in 2H 2026, intended to add commercial cash flows and diversify revenue; not yet contributing.

Recent performance

Q2 2026 revenue was $4.6 million, down from $27.6 million in Q3 2025 and $2.5 million in Q4 2025. The company reported a net loss of $89.2 million for the six months ended June 30, 2026, with an accumulated deficit of $1,171.2 million. Royalty revenue from Jazz and BeOne was $1.8 million in Q2 2026. Full-year 2025 revenue was $106.0 million with a net loss of $81.1 million. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $322.5 million.

Strategy

Zymeworks is executing a royalty-driven asset aggregation strategy, seeking to acquire or license healthcare assets that generate milestone and royalty cash flows. It plans to selectively acquire programs or companies, citing the pending Theravance acquisition, and to return capital via share repurchases, having repurchased $49.4 million of shares as of August 4, 2026 under a 2026 program. The company emphasizes risk-sharing partnerships and disciplined capital allocation, with a multi-year operating expense plan aligned to strategic priorities. It continues internal R&D on MSAT and ADC platforms.

Risks

• Unproven royalty strategy — The company states its royalty-driven asset aggregation strategy is unproven and may not be successful.
• Dependence on zanidatamab — Near-term revenue depends on zanidatamab royalties and a U.S. approval milestone tied to an August 25, 2026 PDUFA date.
• Acquisition integration — The proposed Theravance acquisition could disrupt the business and dilute stockholders, and is subject to closing conditions.
• Losses and cash burn — Zymeworks reported a $89.2 million net loss for the first half of 2026 and expects continued operating losses in the near to medium term.

Outlook

Management points to the August 25, 2026 U.S. PDUFA date for zanidatamab in 1L HER2+ GEA as a potential $250 million milestone, with up to $190 million in additional global regulatory milestones. The Theravance acquisition is expected to close in 2H 2026 and add commercial cash flows. Top-line overall survival results from the HERIZON-GEA-01 doublet regimen are expected in Q3 2026, and EmpowHER-303 enrollment is expected to complete in mid-2027. The company says its existing cash resources fund operations for at least the next twelve months.